screening test to detect a deficiency of 1 or more of the clotting factors of the extrinsic coagulation system (I, II, V, VII, X) due to hereditary deficiency or acquired conditions such as liver disease, vitamin K deficiency, or a specific factor inhibitor
确定延长凝血酶蛋白时间,因子缺乏与因子抑制剂的原因
仅作为反射订购。有关更多信息,请参见:
一种l你pp/ Lupus Anticoagulant Profile, Plasma
ALBLD / BLEEDING DIATHESIS CRUPER,LIMITD,等离子体
一种一种tHr/ Thrombophilia Profile, Plasma
APROL /长时间的凝块时间轮廓,等离子体
ADIC/散布的血管内凝血/血管内凝结和纤维蛋白解(DIC/ICF)剖面,血浆
plasma Na Cit
应注意肝素或香豆素疗法。
仅作为反射订购。有关更多信息,请参见:
一种l你pp/ Lupus Anticoagulant Profile, Plasma
ALBLD / BLEEDING DIATHESIS CRUPER,LIMITD,等离子体
一种一种tHr/ Thrombophilia Profile, Plasma
APROL /长时间的凝块时间轮廓,等离子体
ADIC/散布的血管内凝血/血管内凝结和纤维蛋白解(DIC/ICF)剖面,血浆
严重的溶血 | 拒绝 |
脂肪血症 | 拒绝 |
大黄色 | 拒绝 |
specimen Type | 温度 | 时间 | 特殊容器 |
---|---|---|---|
plasma Na Cit | 冷冻(首选) | 14天 |
screening test to detect a deficiency of 1 or more of the clotting factors of the extrinsic coagulation system (I, II, V, VII, X) due to hereditary deficiency or acquired conditions such as liver disease, vitamin K deficiency, or a specific factor inhibitor
确定延长凝血酶蛋白时间,因子缺乏与因子抑制剂的原因
this test is only performed when the prothrombin time (PT) is abnormally prolonged. See PTSC / Prothrombin Time (PT), Plasma for an interpretation of results.
仅作为反射订购。有关更多信息,请参见:
一种l你pp/ Lupus Anticoagulant Profile, Plasma
ALBLD / BLEEDING DIATHESIS CRUPER,LIMITD,等离子体
一种一种tHr/ Thrombophilia Profile, Plasma
APROL /长时间的凝块时间轮廓,等离子体
ADIC/散布的血管内凝血/血管内凝结和纤维蛋白解(DIC/ICF)剖面,血浆
9.4-12.5秒
凝结凝集素时间(PT)的延长可能是由于1或更多的凝血因子(可获得或先天性的)或存在凝结抑制剂(例如肝素,狼疮抗凝剂),一种“非特异性”抑制剂的抑制剂,可能发生。例如单克隆免疫球蛋白或特定的凝血因子抑制剂。
ptmixing study, using equal volume patient and normal pool plasma, may be performed on specimens with a prolonged PT to assist in differentiating coagulation factor deficiencies from coagulation inhibitors. Correction of the PT mix to within the normal reference range usually indicates a coagulation factor deficiency (normal plasma in the mixture ensures at least 50% activity of all coagulation factors). If the prolonged PT is due to an inhibitor (specific coagulation factor inhibitor, lupus anticoagulant, heparin, etc), the PT mix typically fails to correct a prolonged PT. However, the presence of a weak inhibitor may be missed by the PT mixing study.
对PT和PT混合研究结果的准确解释通常需要进行额外的测试。例如,凝血酶时间(TT)测试有助于识别或排除肝素的存在,血小板中和程序(PNP,使用修改后的APTT方法)用于识别或排除狼疮抗凝剂,激活的部分血栓素(APPTT)和稀释和稀释Russell Viper毒液时间(DRVVT),用于进一步评估常见的凝胶途径,以及用于检测和识别缺乏或异常因素的凝结因子测定。这些测定可作为特殊凝血实验室中反身和解释性测试面板的组成部分提供:
一种l你pp/ Lupus Anticoagulant Profile, Plasma
ALBLD / BLEEDING DIATHESIS CRUPER,LIMITD,等离子体
一种一种tHr/ Thrombophilia Profile, Plasma
APROL /长时间的凝块时间轮廓,等离子体
ADIC/散布的血管内凝血/血管内凝结和纤维蛋白解(DIC/ICF)剖面,血浆
prothrombin time (PT) mixing studies have no utility when the patient PT is normal.
脂肪标本可能会干扰仪器凝块检测机制。
Kamal AH,Tefferi A,Pruthi RK:如何解释和追求异常的凝血酶原时间,激活了部分血栓形成时间和成人流血时间。Mayo Clin Proc 2007 7月:82(7):864-873
the prothrombin time (PT) mix assay is performed on the Instrumentation Laboratory ACL TOP. Patient plasma is combined in a 1:1 ratio with normal pooled plasma then incubated. After a specified incubation time, a PT reagent containing phospholipid, calcium chloride, buffer and a preservative is added to trigger the coagulation process in the mixture. Subsequently, the time to clot formation is measured optically using a wavelength of 671 nm.(Package insert: HemosIL RecombiPlasTin 2G Instrumentation Laboratory Company, Lexington, MA, R0, 09/2007)
从星期一到星期五
this test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.
85611
test Id | 测试订单名称 | 订单loinc值 |
---|---|---|
PTMSC | ptmix 1:1 | 5959-2 |
result Id | 测试结果名称 | 结果lainc值
仅适用于最初由表演实验室报告的度量单位表达的结果。这些值不适用于转换为其他度量单位的结果。
|
---|---|---|
PTMSC | ptmix 1:1 | 5959-2 |